论文部分内容阅读
目的:了解长江流域治疗骨质疏松症药物的应用现状和发展趋势,供临床用药及相关企业参考。方法:利用Microsoft visual foxpro9.0 SP2软件,按金额消耗排序法,分别统计治疗骨质疏松症药物的总金额、各亚类用药金额及占总用药金额的百分比,用药金额排名前10位的药品和生产厂商。结果:1999-2008年长江流域治疗骨质疏松症药物的用药金额呈逐年上升趋势,但在总用药金额中的百分比呈逐年下降趋势;在各亚类药品中,只有双磷酸盐类呈上升趋势,活性维生素D类和钙制剂下降趋势明显;排名前10位的药品中,钙尔奇D呈下降趋势,罗盖全、密盖息从2003年起一直位居前2位,双磷酸盐类有较多品种进入前10位,且排名逐年上升,其中福善美从2006年起位居第3位。排名前10位的生产厂商中,外资和合资企业占绝大多数。结论:随着临床医生和普通百姓对骨质疏松症的进一步认识,治疗骨质疏松症药物具有广阔的应用前景。国产产品具有很大的市场提升空间。
Objective: To understand the application status and development trend of the treatment of osteoporosis drugs in the Yangtze River Basin for the reference of clinical medication and related enterprises. Methods: Using Microsoft visual foxpro9.0 SP2 software, according to the amount of consumption ranking method, the total amount of drugs for the treatment of osteoporosis, the amount of each sub-category and the percentage of the total amount of medication, the top 10 drugs And manufacturers. Results: The amount of drugs used for the treatment of osteoporosis in the Yangtze River Valley increased year by year from 1999 to 2008, but the percentage of the total amount of medication decreased year by year. Only the bisphosphonates in the sub-categories showed an upward trend , Active vitamin D and calcium preparations showed a declining trend. Among the top 10 drugs, the Ca (superscript 2 +) D showed a decreasing trend. Luo Gai Quan and Mi Gai Xi kept the top two positions since 2003, while bisphosphonates There are more varieties into the top 10, and rankings increased year by year, of which Fosun beauty since 2006 ranked No. 3. Top 10 manufacturers, foreign and joint ventures accounted for the vast majority. Conclusion: With the further understanding of osteoporosis by clinicians and ordinary people, the treatment of osteoporosis drugs has broad application prospects. Domestic products have a great market to enhance space.